These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


946 related items for PubMed ID: 15846292

  • 1. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
    Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, Harrison MJ, Ho V, Alyea E, Lee SJ, Soiffer R, Sonis S, Antin JH.
    Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A.
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [Abstract] [Full Text] [Related]

  • 5. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia.
    Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM.
    J Clin Oncol; 2004 Apr 01; 22(7):1268-75. PubMed ID: 15051775
    [Abstract] [Full Text] [Related]

  • 6. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwartz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP, Cornetta K, Fausel CA, Farag SS.
    Biol Blood Marrow Transplant; 2011 Jun 01; 17(6):916-22. PubMed ID: 20932925
    [Abstract] [Full Text] [Related]

  • 7. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate.
    Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R, King B, Macgregor L, Holdsworth R, McCluskey J, Tait BD.
    Bone Marrow Transplant; 2006 Apr 01; 37(8):773-9. PubMed ID: 16518429
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, Itälä-Remes M, Remberger M, Mattsson J.
    Haematologica; 2016 Nov 01; 101(11):1417-1425. PubMed ID: 27662016
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul 01; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 13. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation.
    Nevill TJ, Tirgan MH, Deeg HJ, Klingemann HG, Reece DE, Shepherd JD, Barnett MJ, Phillips GL.
    Bone Marrow Transplant; 1992 May 01; 9(5):349-54. PubMed ID: 1617319
    [Abstract] [Full Text] [Related]

  • 14. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
    Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, Federowicz I, Tomaszewska A, Piatkowska-Jakubas B, Wrzesien-Kus A, Bieniaszewska M, Duda D, Szydlo R, Halaburda K, Szczepinski A, Lange A, Hellman A, Robak T, Skotnicki A, Jedrzejczak WW, Walewski J, Holowiecki J, Komarnicki M, Dmoszynska A, Warzocha K, Marianska B.
    Bone Marrow Transplant; 2007 Nov 01; 40(10):983-8. PubMed ID: 17846600
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD.
    Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K, Shiratori S, Ibata M, Shono Y, Shigematsu A, Obara M, Fujimoto K, Endo T, Nishio M, Kondo T, Hashino S, Tanaka J, Asaka M, Imamura M.
    Bone Marrow Transplant; 2012 Feb 01; 47(2):258-64. PubMed ID: 21423118
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C, Ratanatharathorn V, Adams P, Braun T, Silver S, Ayash L, Carson E, Eisbruch A, Dawson LA, McDonagh K, Ferrara J, Uberti J.
    Bone Marrow Transplant; 2001 Apr 01; 27(8):801-7. PubMed ID: 11477436
    [Abstract] [Full Text] [Related]

  • 17. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
    Uberti JP, Silver SM, Adams PT, Jacobson P, Scalzo A, Ratanatharathorn V.
    Bone Marrow Transplant; 1997 Jun 01; 19(12):1233-8. PubMed ID: 9208118
    [Abstract] [Full Text] [Related]

  • 18. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):704-17. PubMed ID: 19450755
    [Abstract] [Full Text] [Related]

  • 19. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group.
    Gori E, Arpinati M, Bonifazi F, Errico A, Mega A, Alberani F, Sabbi V, Costazza G, Leanza S, Borrelli C, Berni M, Feraut C, Polato E, Altieri MC, Pirola E, Loddo MC, Banfi M, Barzetti L, Calza S, Brignoli C, Bandini G, De Vivo A, Bosi A, Baccarani M.
    Bone Marrow Transplant; 2007 Mar 01; 39(6):347-52. PubMed ID: 17277790
    [Abstract] [Full Text] [Related]

  • 20. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Huang XJ, Jiang Q, Chen H, Xu L, Liu D, Chen Y, Han W, Zhang Y, Liu K, Lu D.
    Bone Marrow Transplant; 2005 Aug 01; 36(4):343-8. PubMed ID: 15968295
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 48.